Latest Earnings Results: Q2 '26
Estimated EPS
-$0.09
Reported EPS
$0.60
Surprise
+805.88%
Estimated Rev
$177.5M
Reported Rev
$234.3M
Surprise
+32%
• Reported GAAP EPS of -$3.49 down -1486.36% YoY • Reported revenue of $234.3M up 66.29% YoY • Emergent BioSolutions Inc. updated its full year 2026 forecast, now expecting total revenues of $645 million to $675 million, adjusted net income of $10 million to $30 million, and adjusted EBITDA of $130 million to $150 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.39 | -- | -- | N/A |
Q2 '26 | -$0.09 | $0.60 | 805.88% | BEAT |
Q1 '26 | -$0.25 | $0.21 | 184.00% | BEAT |
Q4 '25 | $0.11 | -$0.43 | -490.91% | MISSED |
Q3 '25 | -$0.07 | $1.06 | 1689.99% | BEAT |